Literature DB >> 24906862

Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.

Jithin Yohannan1, Bing He2, Jiangxia Wang1, Gregory Greene1, Yvette Schein1, Harran Mkocha3, Beatriz Munoz1, Thomas C Quinn4, Charlotte Gaydos5, Sheila K West1.   

Abstract

PURPOSE: We detected spatial clustering of households with Chlamydia trachomatis infection (CI) and active trachoma (AT) in villages undergoing mass treatment with azithromycin (MDA) over time.
METHODS: We obtained global positioning system (GPS) coordinates for all households in four villages in Kongwa District, Tanzania. Every 6 months for a period of 42 months, our team examined all children under 10 for AT, and tested for CI with ocular swabbing and Amplicor. Villages underwent four rounds of annual MDA. We classified households as having ≥1 child with CI (or AT) or having 0 children with CI (or AT). We calculated the difference in the K function between households with and without CI or AT to detect clustering at each time point.
RESULTS: Between 918 and 991 households were included over the 42 months of this analysis. At baseline, 306 households (32.59%) had ≥1 child with CI, which declined to 73 households (7.50%) at 42 months. We observed borderline clustering of households with CI at 12 months after one round of MDA and statistically significant clustering with growing cluster sizes between 18 and 24 months after two rounds of MDA. Clusters diminished in size at 30 months after 3 rounds of MDA. Active trachoma did not cluster at any time point.
CONCLUSIONS: This study demonstrates that CI clusters after multiple rounds of MDA. Clusters of infection may increase in size if the annual antibiotic pressure is removed. The absence of growth after the three rounds suggests the start of control of transmission. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  Chlamydia trachomatis; azithromycin; trachoma

Mesh:

Substances:

Year:  2014        PMID: 24906862      PMCID: PMC4580214          DOI: 10.1167/iovs.14-14148

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  Eliminating blinding trachoma.

Authors:  Joseph A Cook
Journal:  N Engl J Med       Date:  2008-04-24       Impact factor: 91.245

2.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

3.  The household distribution of trachoma in a Tanzanian village: an application of GIS to the study of trachoma.

Authors:  S R Polack; A W Solomon; N D E Alexander; P A Massae; S Safari; J F Shao; A Foster; D C Mabey
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-03       Impact factor: 2.184

4.  Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?

Authors:  Sheila K West; Dianne Stare; Harran Mkocha; Beatriz Munoz; Charlotte Gaydos; Thomas C Quinn
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

Review 5.  Global data on blindness.

Authors:  B Thylefors; A D Négrel; R Pararajasegaram; K Y Dadzie
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

6.  Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.

Authors:  Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Ansumana Sillah; Sandra Cohuet; Angels Natividad; Neal D E Alexander; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

Review 7.  Trachoma: global magnitude of a preventable cause of blindness.

Authors:  S P Mariotti; D Pascolini; J Rose-Nussbaumer
Journal:  Br J Ophthalmol       Date:  2008-12-19       Impact factor: 4.638

8.  Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.

Authors:  Jithin Yohannan; Beatriz Munoz; Harran Mkocha; Charlotte A Gaydos; Robin Bailey; Thomas A Lietman; Thomas Quinn; Sheila K West
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

9.  A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.

Authors:  Sheila K West; Robin Bailey; Beatriz Munoz; Tansy Edwards; Harran Mkocha; Charlotte Gaydos; Thomas Lietman; Travis Porco; David Mabey; Thomas C Quinn
Journal:  PLoS Negl Trop Dis       Date:  2013-08-29

10.  Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study.

Authors:  Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Neal D E Alexander; Ansumana Sillah; Hannah Faal; Sheila K West; Allen Foster; Gordon J Johnson; David C W Mabey; Robin L Bailey
Journal:  Lancet       Date:  2005 Apr 9-15       Impact factor: 79.321

View more
  7 in total

1.  A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.

Authors:  Daniel P Morberg; Wondu Alemayehu; Muluken Melese; Takele Lakew; Alemayehu Sisay; Zhaoxia Zhou; Vicky Cevallos; Catherine E Oldenburg; Travis C Porco; Thomas M Lietman; Jeremy D Keenan
Journal:  Ophthalmic Epidemiol       Date:  2018-08-28       Impact factor: 1.648

2.  The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.

Authors:  Anna R Last; Sarah E Burr; Emma Harding-Esch; Eunice Cassama; Meno Nabicassa; Chrissy H Roberts; David C W Mabey; Martin J Holland; Robin L Bailey
Journal:  Parasit Vectors       Date:  2017-12-28       Impact factor: 3.876

3.  'If an Eye Is Washed Properly, It Means It Would See Clearly': A Mixed Methods Study of Face Washing Knowledge, Attitudes, and Behaviors in Rural Ethiopia.

Authors:  Kristen Aiemjoy; Nicole E Stoller; Sintayehu Gebresillasie; Ayalew Shiferaw; Zerihun Tadesse; Tegene Sewnet; Bezuayehu Ayele; Melsew Chanyalew; Kelly Callahan; Aisha Stewart; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan; Catherine E Oldenburg
Journal:  PLoS Negl Trop Dis       Date:  2016-10-27

Review 4.  The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.

Authors:  Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2016-10-26

5.  Spatial clustering of high load ocular Chlamydia trachomatis infection in trachoma: a cross-sectional population-based study.

Authors:  Anna Last; Sarah Burr; Neal Alexander; Emma Harding-Esch; Chrissy H Roberts; Meno Nabicassa; Eunice Teixeira da Silva Cassama; David Mabey; Martin Holland; Robin Bailey
Journal:  Pathog Dis       Date:  2017-07-31       Impact factor: 3.166

Review 6.  Progress on application of spatial epidemiology in ophthalmology.

Authors:  Cong Li; Kang Chen; Kaibo Yang; Jiaxin Li; Yifan Zhong; Honghua Yu; Yajun Yang; Xiaohong Yang; Lei Liu
Journal:  Front Public Health       Date:  2022-08-10

7.  Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data.

Authors:  Christine Tedijanto; Solomon Aragie; Zerihun Tadesse; Mahteme Haile; Taye Zeru; Scott D Nash; Dionna M Wittberg; Sarah Gwyn; Diana L Martin; Hugh J W Sturrock; Thomas M Lietman; Jeremy D Keenan; Benjamin F Arnold
Journal:  PLoS Negl Trop Dis       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.